Impact of the SARS-CoV-2-Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial

Authors
Category Primary study
JournalOpen Forum Infectious Diseases
Year 2022
This article has no abstract
Epistemonikos ID: 0c5006882e5a2f4cb5bbc904d283028b3aaa90d5
First added on: Feb 15, 2025